The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV : results from the EuroSIDA study. / Mocroft, Amanda; Miro, Jose M.; Wandeler, Gilles; Llibre, Josep M; Boyd, Anders; van Bremen, Kathrin; Beniowski, Marek; Mikhalik, Julia; Cavassini, Matthias; Maltez, Fernando; Duvivier, Claudine; Uberti Foppa, Caterina; Knysz, Brygida; Bakowska, Elzbieta; Kuzovatova, Elena; Domingo, Pere; Zagalo, Alexandra; Viard, Jean-Paul; Degen, Olaf; Milinkovic, Ana; Benfield, Thomas; Peters, Lars; Kronborg, G.; Gerstoft, J.; The EuroSIDA Study Group.
In: HIV Medicine, Vol. 23, No. 6, 2022, p. 585-598.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV
T2 - results from the EuroSIDA study
AU - Mocroft, Amanda
AU - Miro, Jose M.
AU - Wandeler, Gilles
AU - Llibre, Josep M
AU - Boyd, Anders
AU - van Bremen, Kathrin
AU - Beniowski, Marek
AU - Mikhalik, Julia
AU - Cavassini, Matthias
AU - Maltez, Fernando
AU - Duvivier, Claudine
AU - Uberti Foppa, Caterina
AU - Knysz, Brygida
AU - Bakowska, Elzbieta
AU - Kuzovatova, Elena
AU - Domingo, Pere
AU - Zagalo, Alexandra
AU - Viard, Jean-Paul
AU - Degen, Olaf
AU - Milinkovic, Ana
AU - Benfield, Thomas
AU - Peters, Lars
AU - Kronborg, G.
AU - Gerstoft, J.
AU - The EuroSIDA Study Group
N1 - Publisher Copyright: © 2021 British HIV Association.
PY - 2022
Y1 - 2022
N2 - Objectives: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH). Methods: All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit. Results: Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94–8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47–12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00–1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00–1.89) and NHL (aIRR 2.57; 95% CI 1.16–5.68). There was no significant association between HBV and lung or anal cancer. Conclusions: We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.
AB - Objectives: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH). Methods: All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit. Results: Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94–8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47–12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00–1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00–1.89) and NHL (aIRR 2.57; 95% CI 1.16–5.68). There was no significant association between HBV and lung or anal cancer. Conclusions: We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.
KW - HBV DNA
KW - hepatitis B
KW - nonliver cancer
U2 - 10.1111/hiv.13210
DO - 10.1111/hiv.13210
M3 - Journal article
C2 - 34889022
AN - SCOPUS:85120965873
VL - 23
SP - 585
EP - 598
JO - HIV Medicine
JF - HIV Medicine
SN - 1464-2662
IS - 6
ER -
ID: 329431150